Literature DB >> 12123810

PP1/PP2A phosphatases inhibitors okadaic acid and calyculin A block ERK5 activation by growth factors and oxidative stress.

Lourdes Garcia1, Fatima Garcia, Franc Llorens, Mercedes Unzeta, Emilio Itarte, Néstor Gómez.   

Abstract

Okadaic acid is an inhibitor of the protein Ser/Thr phosphatases PP1 and PP2A, which blocks the activation of extracellular signal-regulated protein kinase 5 (ERK5), a member of the MAP kinase family activated by growth factors and several types of stressors. The blocking of ERK5 activation by okadaic acid was observed in HeLa cells exposed to epidermal growth factor and H(2)O(2) as well as in PC12 cells stimulated by nerve growth factor and H(2)O(2). Calyculin A, another PP1 and PP2A inhibitor, behaved similarly although these compounds are not structurally related. This suggests that either PP1 or PP2A or both are necessary for ERK5 activation. Protein kinase C (PKC) acts as a negative regulator of the ERK5 activation pathway, however our data suggest that the effects of PKC and the phosphatase are unrelated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12123810     DOI: 10.1016/s0014-5793(02)02950-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  20 in total

1.  Phosphorylation-dependent interaction of SATB1 and PIAS1 directs SUMO-regulated caspase cleavage of SATB1.

Authors:  Joseph-Anthony T Tan; Jing Song; Yuan Chen; Linda K Durrin
Journal:  Mol Cell Biol       Date:  2010-03-29       Impact factor: 4.272

Review 2.  The relationship between the MMP system, adrenoceptors and phosphoprotein phosphatases.

Authors:  A Rietz; Jp Spiers
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 3.  Frontier of epilepsy research - mTOR signaling pathway.

Authors:  Chang Hoon Cho
Journal:  Exp Mol Med       Date:  2011-05-31       Impact factor: 8.718

4.  Targeting the BMK1 MAP kinase pathway in cancer therapy.

Authors:  Qingkai Yang; Jiing-Dwan Lee
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

5.  Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.

Authors:  Anupriya Agarwal; Ryan J MacKenzie; Raffaella Pippa; Christopher A Eide; Jessica Oddo; Jeffrey W Tyner; Rosalie Sears; Michael P Vitek; María D Odero; Dale J Christensen; Brian J Druker
Journal:  Clin Cancer Res       Date:  2014-01-16       Impact factor: 12.531

Review 6.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

7.  Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome.

Authors:  Soong Ho Kim; Julie A Markham; Ivan Jeanne Weiler; William T Greenough
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-10       Impact factor: 11.205

8.  Activation of the transcription factor carbohydrate-responsive element-binding protein by glucose leads to increased pancreatic beta cell differentiation in rats.

Authors:  A Soggia; K Flosseau; P Ravassard; G Szinnai; R Scharfmann; G Guillemain
Journal:  Diabetologia       Date:  2012-07-05       Impact factor: 10.122

9.  Cross-talk between ciliary epithelium and trabecular meshwork cells in-vitro: a new insight into glaucoma.

Authors:  Natalie Lerner; Elie Beit-Yannai
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

10.  Intermittent hypoxia-induced protein phosphatase 2A activation reduces PC12 cell proliferation and differentiation.

Authors:  Tsung-I Chen; Hung-Wen Chiu; Yi-Chung Pan; Shih-Ting Hsu; Jian-Hong Lin; Kun-Ta Yang
Journal:  J Biomed Sci       Date:  2014-05-16       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.